Target intelligence / Profile preview

Shigella surface antigens

Molecular classification
Bacterial surface protein, Lipopolysaccharide, Glycan
01

Overview

Shigella surface antigens are a complex array of molecules located on the outer membrane of Shigella species, primarily comprising the O-antigen component of lipopolysaccharide (LPS) and the invasion plasmid antigens (Ipa) associated with the Type III secretion system (T3SS) [Mani et al., 2016]. These antigens are essential for the pathogenesis of shigellosis, facilitating bacterial adhesion, invasion of the colonic epithelium, and subsequent escape from the phagocytic vacuole [Schroeder and Hilbi, 2008]. The O-antigen is the primary target for protective humoral immunity and defines the various serotypes of Shigella, such as S. flexneri and S. sonnei [Phalipon and Sansonetti, 2007]. Therapeutic interventions targeting these antigens include glycoconjugate vaccines, which link the O-antigen to carrier proteins to enhance immunogenicity, and live-attenuated vaccines that express these surface components [Cohen et al., 2022]. Additionally, monoclonal antibodies are being explored to neutralize the T3SS machinery or the LPS layer directly. A significant challenge in targeting these antigens is the high degree of serotype specificity, necessitating the development of multivalent formulations to ensure broad protection against the diverse strains causing global diarrheal disease [Mani et al., 2016].

Other names
Shigella O-antigenShigella lipopolysaccharideInvasion plasmid antigensIpa proteinsShigella Type III secretion system proteins
02

Mechanism of action

Induction of protective humoral immunity (IgG/IgA) against O-antigen to prevent bacterial colonization and invasion; neutralization of the Type III secretion system to block entry into host epithelial cells.

03

Biological functions

Bacterial pathogenesisCell invasionImmune evasionAdhesion
04

Disease associations

ShigellosisBacillary dysenteryInfection
05

Safety considerations

Serotype-specific protectionReactogenicity of live-attenuated platformsNeed for multivalent formulations
06

Interacting drugs

Flexyn2a

3 more in the full profile.

07

Biomarkers

Serum IgG against O-specific polysaccharideFecal IgA against O-specific polysaccharideIpaB antibody titersIpaC antibody titers

Beyond the preview

Go deeper on Shigella surface antigens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella surface antigens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call